Response to “Weight‐loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk”

Documenti analoghi

• Weight loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk
  di: Léa Karam, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
  di: Yu Mi Kang, et al.
  Pubblicazione: (2025)
• Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
  di: Evan Zeitler, et al.
  Pubblicazione: (2026)
• Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
  di: Suleiman Al Ashi, et al.
  Pubblicazione: (2025)
• Approach to weight management in patients with advanced chronic kidney disease in a real‐life clinical setting
  di: Paola Lockhart Pastor, et al.
  Pubblicazione: (2024)